Mainstay Medical (Euronext Paris: MSTY.PA) is a European medical device company developing an implantable neurostimulation system for the treatment of chronic low back pain (CLBP). Mainstay’s ReActiv8 is intended for use in individuals with CLBP who have failed conventional therapies and are not candidates for spine surgery or stimulation. There are roughly 2.3 million individuals combined in the US and Europe that would be eligible for this therapy if it is approved. The Company filed for CE marking in November 2015 based on positive results from the ReActiv8-A trial and plans to launch an IDE trial to support approval in the US.

Read More